Featured Videos |view more
Gerard A. Silvestri, M.D., a lung cancer pulmonologist at MUSC, led a study that shows that a new biomarker is 98 percent effective at distinguishing benign from malignant lung nodules.
MUSC Health gastrointestinal surgeon Katherine A. Morgan, M.D., discusses the Whipple procedure as a surgical treatment for localized pancreatic cancer.
Carsten Krieg, Ph.D.,discusses how “Instagrams of the immune system,” captured by a new technology, made it possible to identify biomarkers of response to immunotherapy in patients with melanoma.
Study of advanced glycation end produces (AGEs) through dietary and exercise intervention to see if improvement of quality of life decreases tumor recurrence in patients.
Thanks to improved treatments, patients with cancer are living longer. Some of those treatments, however, are associated with cardiotoxicities that can put patients at risk for heart problems.
Raymond N. DuBois MD, dean of the College of Medicine at the Medical University of South Carolina discusses Stand Up to Cancer’s Catalyst Program.
Featured Documents |view more
As part of MUSC's growing transnational genomics program, a genomics tumor board has been created to bring diverse specialists together to help physicians diagnose and manage cancer.
Transanal total mesorectal excision (TaTME) has garnered a great surgery because it represents a reversal of perspective—literally— about how best to excise tumors and the surrounding mesorectal envelope in the lower third of the rectum.
Researchers are using adoptive cell transfer (ACT) to reinforce the ranks of a patient’s own T cells—the body’s warriors—and train them to better target the patient’s cancer.
News that novel T cell–based immunotherapeutic approaches such as immune checkpoint blockade and adoptive cell transfer are achieving durable responses in patients with aggressive cancers has created excitement in the world of cancer research.
Genomics screening can improve the odds for some cancer patients, potentially identifying mutations associated with cancer subtypes for which targeted therapies exist or are in development.
The Hollings Cancer Center at the Medical University of South Carolina is a National Cancer Institute-designated cancer center and the largest academic-based cancer research program in South Carolina. The cancer center comprises more than 120 faculty cancer scientists with an annual research funding portfolio of $44 million and a dedication to reducing the cancer burden in South Carolina. Hollings offers state-of-the-art diagnostic capabilities, therapies and surgical techniques within multidisciplinary clinics that include surgeons, medical oncologists, radiation therapists, radiologists, pathologists, psychologists and other specialists equipped for the full range of cancer care, including more than 200 clinical trials.